I
Innovent Biologics
Biotech & Life Sciences · Suzhou Shi, China · Founded 2011 · IPO 2018
Talent graph
Innovent Biologics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Innovent Biologics has talent and traffic
team presence
across markets
Patent intelligence
$84M patent portfolio · 151 active families
Where Innovent Biologics concentrates vs peers
Each axis is a top-10 topic across Innovent Biologics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
Innovent Biologics's 2 investments and acquisitions.
Every disclosed deal where Innovent Biologics appeared as a backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
2 deals across Innovent Biologics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
02 · Portfolio market map
Innovent Biologics's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
What the market is saying about Innovent Biologics
An AI-synthesized read of the highest-engagement posts about Innovent Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Innovent Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.